[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"biomarker:ms4a1-gene":3},{"name":4,"total":5,"recruiting":6,"trials":7},"MS4A1 Gene",48,39,[8,16,23,29,35,41,48,54,60,66,73,79,85,90,96,102,108,114,120,125,130,136,141,146,152,158,164,170,176,182,188,193,199,205,211,217,223,229,235,241,248,253,259,265,272,279,286,292],{"nct_id":9,"title":10,"phases":11,"status":13,"updated_at":14,"content_modified":15},"NCT05886036","Comparing the Effectiveness of the Immunotherapy Agents Rituximab or Mosunetuzumab in Patients With Nodular Lymphocyte-Predominant Hodgkin Lymphoma, NORM Trial",[12],"Phase 2","RECRUITING","2026-08-26T02:18:39.640967Z","2026-07-30T01:46:14.465297Z",{"nct_id":17,"title":18,"phases":19,"status":13,"updated_at":21,"content_modified":22},"NCT03150693","Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia",[20],"Phase 3","2026-08-26T02:16:51.982021Z","2026-07-05T05:32:16.770812Z",{"nct_id":24,"title":25,"phases":26,"status":13,"updated_at":27,"content_modified":28},"NCT07321652","Testing the Addition of Anti-Cancer Drug Sonrotoclax, to the Standard Treatment Zanubrutinib, for Previously Untreated CLL\u002FSLL",[20],"2026-08-26T02:19:14.560989Z","2026-06-17T02:29:30.059389Z",{"nct_id":30,"title":31,"phases":32,"status":13,"updated_at":33,"content_modified":34},"NCT06091865","A Study to Compare How Well Odronextamab Combined With Chemotherapy Works and How Safe it is Against Rituximab Combined With Chemotherapy, in Adult Patients With Previously Untreated Diffuse Large B-cell Lymphoma",[20],"2026-08-26T02:15:41.377360Z","2026-05-29T15:36:40.167745Z",{"nct_id":36,"title":37,"phases":38,"status":13,"updated_at":39,"content_modified":40},"NCT05786040","Tafasitamab and Rituximab for Front-Line Treatment of Post-Transplant Lymphoproliferative Disorder",[12],"2026-08-26T02:15:51.395565Z","2026-05-05T02:43:29.700475Z",{"nct_id":42,"title":43,"phases":44,"status":13,"updated_at":46,"content_modified":47},"NCT05533775","A Study to Evaluate Glofitamab Monotherapy and Glofitamab + Chemoimmunotherapy in Pediatric and Young Adult Participants With Relapsed\u002FRefractory Mature B-Cell Non-Hodgkin Lymphoma",[45],"Phase 1\u002FPhase 2","2026-08-26T02:15:53.461103Z","2026-05-05T02:43:29.390938Z",{"nct_id":49,"title":50,"phases":51,"status":13,"updated_at":52,"content_modified":53},"NCT06350318","Rituximab and Zanubrutinib in Patients With Indolent B-cell Lymphomas",[12],"2026-08-26T02:17:56.243868Z","2026-05-05T02:43:29.381547Z",{"nct_id":55,"title":56,"phases":57,"status":13,"updated_at":58,"content_modified":59},"NCT06954805","Defining ctDNA Metrics in Posttransplant Lymphoproliferative Disorder (PTLD)",[12],"2026-08-26T02:17:52.450442Z","2026-05-05T02:43:29.355601Z",{"nct_id":61,"title":62,"phases":63,"status":13,"updated_at":64,"content_modified":65},"NCT06594939","Mosunetuzumab and Polatuzumab Vedotin With Split-Dose CHP Chemotherapy for Elderly Patients With Diffuse Large B-Cell Lymphoma",[12],"2026-08-26T02:18:13.438956Z","2026-05-05T02:43:29.130167Z",{"nct_id":67,"title":68,"phases":69,"status":13,"updated_at":71,"content_modified":72},"NCT05169515","A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Mosunetuzumab or Glofitamab in Combination With CC-220 and\u002For CC-99282 in Participants With B-Cell Non-Hodgkin Lymphoma",[70],"Phase 1","2026-08-03T02:58:35.674064Z","2026-05-05T02:43:28.970343Z",{"nct_id":74,"title":75,"phases":76,"status":13,"updated_at":77,"content_modified":78},"NCT06091254","A Trial to Learn if Odronextamab is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Different Types of Chemotherapy for Adult Participants With Previously Untreated Follicular Lymphoma",[20],"2026-08-26T02:18:58.141497Z","2026-05-05T02:43:28.416255Z",{"nct_id":80,"title":81,"phases":82,"status":13,"updated_at":83,"content_modified":84},"NCT06792825","HM2023-43:Ph 2 Trial of Tafasitamab With Lenalidomide+Rituximab in Treatment-naive FL and MZL",[12],"2026-08-26T02:18:08.005333Z","2026-05-05T02:43:28.357811Z",{"nct_id":86,"title":87,"phases":88,"status":13,"updated_at":46,"content_modified":89},"NCT05010564","Trivalent CAR-T Cell in Acute B-Lineage Leukemia (TRICAR-ALL)",[70],"2026-05-05T02:43:28.287884Z",{"nct_id":91,"title":92,"phases":93,"status":13,"updated_at":94,"content_modified":95},"NCT06054776","Acalabrutinib, Obinutuzumab, and Glofitamab for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma",[12],"2026-08-26T02:16:02.918558Z","2026-05-05T02:43:28.179276Z",{"nct_id":97,"title":98,"phases":99,"status":13,"updated_at":100,"content_modified":101},"NCT06453044","Mosunetuzumab and Polatuzumab Vedotin for the Treatment of Patients With Relapsed or Refractory Grade 1-3a Follicular Lymphoma",[12],"2026-08-26T02:18:27.904411Z","2026-05-05T02:43:28.118057Z",{"nct_id":103,"title":104,"phases":105,"status":13,"updated_at":106,"content_modified":107},"NCT07257055","Phase 2 Study of BTKi-Rituximab Induction Followed by Glofitamab Consolidation in High Risk Untreated MCL Patients - WINDOW-4 Study",[12],"2026-08-26T02:18:12.612955Z","2026-05-05T02:43:27.813302Z",{"nct_id":109,"title":110,"phases":111,"status":13,"updated_at":112,"content_modified":113},"NCT07128641","Odronextamab in Low Tumor Volume Advanced FL",[12],"2026-08-26T02:18:24.494016Z","2026-05-05T02:43:27.423636Z",{"nct_id":115,"title":116,"phases":117,"status":13,"updated_at":118,"content_modified":119},"NCT06263491","Phase II Study of Pirtobrutinib, Rituximab (PR) in Previously Untreated Low and Intermediate Risk MCL (Mantle Cell Lymphoma) Patients",[12],"2026-08-26T02:17:55.355429Z","2026-05-05T02:43:27.392848Z",{"nct_id":121,"title":122,"phases":123,"status":13,"updated_at":83,"content_modified":124},"NCT06175000","Maintenance Obinutuzumab in Treating Patients With Central Nervous System Lymphoma Who Have Achieved a Complete or Partial Response",[12],"2026-05-05T02:43:27.247939Z",{"nct_id":126,"title":127,"phases":128,"status":13,"updated_at":77,"content_modified":129},"NCT06672705","Epcoritamab for the Treatment of Relapsed or Refractory Post Transplant Lymphoproliferative Disorders",[70],"2026-05-05T02:35:31.915210Z",{"nct_id":131,"title":132,"phases":133,"status":13,"updated_at":134,"content_modified":135},"NCT07218510","Venetoclax and Obinutuzumab Followed by Epcoritamab for the Treatment of Untreated Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma, LonGEVity Trial",[12],"2026-08-26T02:16:15.345907Z","2026-05-05T02:35:31.644407Z",{"nct_id":137,"title":138,"phases":139,"status":13,"updated_at":46,"content_modified":140},"NCT06918431","Asparaginase Erwinia Chrysanthemi With Chemotherapy for the Treatment of High-Risk Adults With Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma",[12],"2026-04-29T02:57:57.072943Z",{"nct_id":142,"title":143,"phases":144,"status":13,"updated_at":112,"content_modified":145},"NCT06364423","Anti-CD19 Chimeric Antigen Receptor T-Cell Immunotherapy for Leukemias",[45],"2026-07-05T05:32:16.752213Z",{"nct_id":147,"title":148,"phases":149,"status":13,"updated_at":150,"content_modified":151},"NCT03571568","A Study of BI-1206 in Combination With Rituximab With or Without Acalabrutinib in Subjects With Indolent B-Cell NHL",[45],"2026-08-26T02:18:38.077159Z","2026-05-05T02:43:29.721924Z",{"nct_id":153,"title":154,"phases":155,"status":13,"updated_at":156,"content_modified":157},"NCT06458439","Epcoritamab-CAR T Cells for Large B-cell Lymphomas",[12],"2026-08-26T02:17:54.420226Z","2026-05-05T02:43:28.016787Z",{"nct_id":159,"title":160,"phases":161,"status":13,"updated_at":162,"content_modified":163},"NCT07283679","Phase I\u002FII Trial of ONC-PluReceptor NK Cells With Epcoritamab and Tafasitamab for Patients With Recurrent or Refractory B-cell Non-Hodgkin Lymphoma",[45],"2026-08-26T02:18:03.638950Z","2026-05-05T02:43:27.977643Z",{"nct_id":165,"title":166,"phases":167,"status":13,"updated_at":168,"content_modified":169},"NCT06905509","Epcoritamab Plus Standard of Care Platinum-Based Chemotherapy and Autologous Hematopoietic Cell Transplant for the Treatment of Relapsed or Refractory Large B-cell Lymphoma",[12],"2026-08-26T02:15:13.282904Z","2026-05-05T02:43:27.809747Z",{"nct_id":171,"title":172,"phases":173,"status":13,"updated_at":174,"content_modified":175},"NCT07365306","Epcoritamab, Rituximab, Gemcitabine and Oxaliplatin (R-GemOx) as Salvage Therapy Before Autologous Stem Cell Transplant for the Treatment of Relapsed\u002FRefractory Diffuse Large B-Cell Lymphoma",[12],"2026-08-26T02:16:14.341106Z","2026-05-05T02:43:27.484467Z",{"nct_id":177,"title":178,"phases":179,"status":13,"updated_at":180,"content_modified":181},"NCT05615636","A Phase II Trial of Mosunetuzumab, Polatuzumab, Tafasitamab, and Lenalidomide in Patients With Relapsed B-cell NHL",[12],"2026-08-26T02:17:23.750999Z","2026-05-05T02:43:27.476441Z",{"nct_id":183,"title":184,"phases":185,"status":13,"updated_at":186,"content_modified":187},"NCT06788964","Loncastuximab Tesirine and Rituximab as Bridging Therapy Before Standard-of-care CAR-T Therapy in Patients With Large B-cell Lymphoma (CORAL)",[12],"2026-08-26T02:18:45.196599Z","2026-07-05T05:32:16.700465Z",{"nct_id":189,"title":190,"phases":191,"status":13,"updated_at":174,"content_modified":192},"NCT06542250","A Study to Evaluate Safety, PK, PD and Efficacy of AZD5492, a T Cell-engaging Antibody Targeting CD20 in Subjects With R\u002FR B-Cell Malignancies.",[45],"2026-05-05T02:43:29.470752Z",{"nct_id":194,"title":195,"phases":196,"status":13,"updated_at":197,"content_modified":198},"NCT07188558","A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy",[20],"2026-08-26T02:18:37.277498Z","2026-05-05T02:43:29.052132Z",{"nct_id":200,"title":201,"phases":202,"status":13,"updated_at":203,"content_modified":204},"NCT06209619","CC-99282 + Rituximab Early Post CART for Non-Hodgkin's Lymphoma",[70],"2026-08-26T02:15:10.362237Z","2026-05-05T02:43:28.853554Z",{"nct_id":206,"title":207,"phases":208,"status":13,"updated_at":209,"content_modified":210},"NCT05826535","Study of Rondecabtagene Autoleucel in Aggressive Large B-Cell Lymphoma",[45],"2026-08-26T02:19:30.857183Z","2026-05-05T02:43:28.542914Z",{"nct_id":212,"title":213,"phases":214,"status":13,"updated_at":215,"content_modified":216},"NCT02393157","Obinutuzumab and ICE Chemotherapy in Refractory\u002FRecurrent CD20+ Mature NHL",[12],"2026-08-26T02:17:44.240289Z","2026-05-05T02:43:28.289405Z",{"nct_id":218,"title":219,"phases":220,"status":13,"updated_at":221,"content_modified":222},"NCT04231877","Polatuzumab Vedotin and Combination Chemotherapy With or Without Glofitamab for the Treatment of Untreated Aggressive Large B-cell Lymphoma",[70],"2026-08-03T01:58:01.892442Z","2026-05-05T02:43:28.077600Z",{"nct_id":224,"title":225,"phases":226,"status":13,"updated_at":227,"content_modified":228},"NCT05418088","Genetically Engineered Cells (Anti-CD19\u002FCD20\u002FCD22 CAR T-cells) for the Treatment of Relapsed or Refractory Lymphoid Malignancies",[70],"2026-08-26T02:16:49.565137Z","2026-05-05T02:43:27.982458Z",{"nct_id":230,"title":231,"phases":232,"status":13,"updated_at":233,"content_modified":234},"NCT05990465","LV20.19 CAR T-Cells in Combination With Pirtobrutinib for Relapsed, Refractory B-cell Malignancies",[70],"2026-08-26T02:18:14.396999Z","2026-05-05T02:43:27.263994Z",{"nct_id":236,"title":237,"phases":238,"status":13,"updated_at":239,"content_modified":240},"NCT06693830","ctDNA-guided Therapy Optimization in Newly Diagnosed DLBCL",[],"2026-08-26T02:18:29.369233Z","2026-05-05T02:43:29.733681Z",{"nct_id":242,"title":243,"phases":244,"status":245,"updated_at":246,"content_modified":247},"NCT07662928","Epcoritamab in Combination With Dose Adjusted EPOCH-R for High-risk Burkitt Lymphoma (BL), The BEDROCK Study",[12],"NOT_YET_RECRUITING","2026-08-26T02:15:01.639696Z","2026-07-05T03:45:20.354557Z",{"nct_id":249,"title":250,"phases":251,"status":245,"updated_at":227,"content_modified":252},"NCT07588698","Epcoritamab in Combination With R-CHOP for Patients With Aggressive Non-Hodgkin Lymphoma",[12],"2026-05-29T15:36:40.200627Z",{"nct_id":254,"title":255,"phases":256,"status":245,"updated_at":257,"content_modified":258},"NCT07583810","Non-covalent BTK Inhibitor Nemtabrutinib in Combination With the CD20 Monoclonal Antibody Rituximab for the Treatment of Marginal Zone Lymphoma",[12],"2026-08-26T02:16:32.589113Z","2026-05-29T15:36:40.196726Z",{"nct_id":260,"title":261,"phases":262,"status":245,"updated_at":263,"content_modified":264},"NCT07731789","Tafasitamab and Rituximab for the Treatment of Newly Diagnosed Follicular Lymphoma",[12],"2026-08-26T02:17:48.768272Z","2026-07-30T01:46:14.455065Z",{"nct_id":266,"title":267,"phases":268,"status":269,"updated_at":270,"content_modified":271},"NCT06167642","Retinal Atrophy and Neurofilament Light Chain in People With Multiple Sclerosis Taking Ofatumumab",[],"ENROLLING_BY_INVITATION","2026-08-26T02:16:00.194860Z","2026-06-16T05:54:08.100025Z",{"nct_id":273,"title":274,"phases":275,"status":269,"updated_at":277,"content_modified":278},"NCT06495593","Effects of Ocrelizumab Treatment on Immune Cells in Lymph Nodes in Multiple Sclerosis",[276],"Phase 4","2026-08-26T02:17:39.048487Z","2026-06-16T05:54:07.757786Z",{"nct_id":280,"title":281,"phases":282,"status":283,"updated_at":284,"content_modified":285},"NCT03075696","A Dose Escalation Study of Glofitamab (RO7082859) as a Single Agent and in Combination With Obinutuzumab, Administered After a Fixed, Single Pre-treatment Dose of Obinutuzumab in Participants With Relapsed\u002FRefractory B-cell Non-hodgkin's Lymphoma",[45],"ACTIVE_NOT_RECRUITING","2026-08-03T03:21:44.652451Z","2026-05-05T02:43:28.840989Z",{"nct_id":287,"title":288,"phases":289,"status":283,"updated_at":290,"content_modified":291},"NCT05421663","A Study of JNJ-90014496 in Participants With B-Cell Non-Hodgkin Lymphoma",[45],"2026-08-03T03:30:50.548292Z","2026-05-05T02:43:29.152099Z",{"nct_id":293,"title":294,"phases":295,"status":283,"updated_at":296,"content_modified":297},"NCT05412290","Mosunetuzumab Consolidation Therapy After autoSCT in r\u002Fr Aggressive B Cell Lymphoma",[70],"2026-08-03T03:30:23.638222Z","2026-05-05T02:43:28.878051Z"]